Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 17/20 | 0.66 |
| ▸ | PTPRC | P08575 | 11/20 | 0.66 |
| ▸ | PTPN2 | P17706 | 10/20 | 0.66 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.46 |
| ▸ | PGK1 | P00558 | 2/20 | 0.46 |
| ▸ | PGK2 | P07205 | 2/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945644 | 0.85 | PTPN1 (0.67) | PTPN1PTPRCPTPN2 | |
| SCHEMBL7832780 | 0.73 | PTPN1 (0.60) | PTPN1PTPRCPTPN2 | |
| SCHEMBL4323249 | 0.73 | PTPN1 (0.80) | PTPN1PTPRCPTPN2 | |
| SCHEMBL16871360 | 0.70 | CASR (0.48) | PTPN1PTPRCPTPN2 | |
| SCHEMBL1666355 | 0.67 | CASR (0.50) | — | |
| SCHEMBL6944220 | 0.67 | PGK1 (0.62) | PTPN1PTPRCPTPN2PTPN6PTPN11 | |
| SCHEMBL6946496 | 0.66 | PTPN1 (0.76) | PTPN1PTPRCPTPN2PTPN6PTPN11 | |
| SCHEMBL27820612 | 0.66 | CASR (0.49) | — | |
| SCHEMBL6947737 | 0.66 | PTPN1 (0.76) | PTPN1PTPRCPTPN2PTPN6PTPN11 | |
| SCHEMBL5720317 | 0.65 | CASR (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115729-B1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA INC (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |